iNtRODUCtiON
Giant-cell tumour of bone (GCTB) is a primary bone tumour that presents as an eccentric osteolytic lesion frequently affecting the epiphyseal or subarticular region of long bones, the spine, or the sacrum. GCTB, a type of giant cell-rich lesion of bone, is generally benign; however, atypical GCTB may be associated with multiple local recurrences, multicentricity, pulmonary metastases, or lesions that cannot be removed surgically without causing substantial morbidity. The World Health Organization therefore classifies GCTB as "an aggressive, potentially malignant lesion".
1
GCTB accounts for approximately 5% of all primary bone tumours and approximately 20% of all benign bone tumours. It is also known for its locally aggressive behaviour and high recurrence rates of 15% to 50% after usual curettage only and 2.3% to 20% after curettage with adjuvant treatment (ie, further debridement with a high-speed burr, cryotherapy with liquid nitrogen, chemical debridement with phenol, or bone cementing). When treating GCTB non-surgically with agents such as denosumab, a major concern is that it can be difficult to histologically distinguish between GCTB and giant-cell rich osteosarcoma at initial presentation based on biopsy specimens. Therefore, incomplete surgical excision can be extremely problematic in some cases. Therefore, new developments in therapy for aggressive GCTB have been sought. ). On 13 June 2013, the Food and Drug Administration of the United States approved denosumab (Xgeva injection, for subcutaneous use, Amgen Inc.) for the treatment of adults and skeletally mature adolescents with GCTB that is unresectable or where surgical resection is likely to result in severe morbidity. Nonsurgical treatment also allows better functional capability. Denosumab's approval was based on demonstration of durable objective responses observed in two multicentre open-label trials enrolling adult and skeletally mature adolescents with histologically confirmed, measurable GCTB.
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The present study aimed to perform radiological evaluation of the efficacy of denosumab as a treatment for GCTB with histopathological correlation. There have been no similar studies performed in Hong Kong, and few such studies have been published internationally.
MEtHODS
The present study was a single-centre, retrospective study. Denosumab treatment for GCTB has been offered in our hospital since 2012. All consenting patients with histological confirmation of GCTB were treated with denosumab, after excluding pregnant patients and those with hypocalcaemia. The range of follow-up from diagnosis was 4 to 30 months. The denosumab treatment 6,7 Regular renal function tests were performed for monitoring of blood calcium and phosphate levels. Calcium and vitamin D supplements were also prescribed.
The major adverse drug effects of denosumab include hypocalcaemia, serious infections, suppression of bone turnover including osteonecrosis of the jaw, and atypical femoral fractures. Any treatment-related and dermatologic adverse events were recorded if present.
Serial computed tomography (CT) and magnetic resonance imaging (MRI) assessments were made for the available radiographs for pre-and post-treatment changes. These radiological assessments were made at irregular intervals, subject to clinical judgement by orthopaedic surgeons.
Radiographs and CT results were used to assess changes in tumour size (maximal length, width, and depth) and presence of osteosclerosis by visual inspection. MRI results were used to assess changes in actual tumour size (maximal length, width and depth), presence of an extraosseous soft tissue component, and enhancing tumour area by visual assessment. All factors assessed were categorised as 'decrease', 'no change', or 'increase'.
A retrospective determination of radiological response was performed by radiologists who had received accredited training in musculoskeletal imaging and had 1 to 7 years of experience.
Concomitant histopathological comparisons of the pre-and post-treatment specimens were performed to evaluate the effects of denosumab treatment on overall tumour morphology. The specimens, obtained under fluoroscopic guidance with 14G Murphy coaxial needle and the bone biopsy set, were stained with haematoxylin and eosin and assessed by a consultant pathologist with more than 20 years of experience. Evaluation included the extent of the tumour section composed of mononuclear tumour stromal cells and giant cells and de novo bone matrix.
Tumour response was assessed based on the constellation of findings concluded by the pathologist. When tumour response was deemed adequate, curettage was performed.
RESUltS
A total of 12 patients received denosumab treatment for GCTB from 20 July 2012 to 5 June 2015. The mean age of the patients was 40 (median, 38; range, 21-66) years. After having received four neoadjuvant and one to (Table) .
Clinical Parameters
Although formal assessment of pain and quality of life was not mandated in this study, data collected from 11 (92%) patients reported at least reduced pain or subjective functional improvement. Through regular monitoring of renal function and prescription of calcium and vitamin D supplements, no episode of hypocalcaemia was detected. The denosumab treatment was also generally well tolerated, with no major or minor treatment-related adverse events reported. Abbreviations: CT = computed tomography; MRI = magnetic resonance imaging. 
Radiological Response

(a) (b)
Serial CT assessments demonstrated changes similar to those shown on radiographs, with evidence of bone repair with increased osteosclerosis in four out of four (100%) patients. An example is shown in Figure 4 . Again, none of the lesions showed definite interval change in size.
Serial MRI assessments demonstrated no definite interval change in terms of overall size of tumour, enhancement characteristics, and extent of soft tissue component in nine out of 11 (82%) patients before and after treatment. An example is shown in Figure 5 . Osteosclerosis was not assessed by MRI, as the changes in our patients were subtle and do not correspond well to the extent of osteosclerosis that we see on radiographs or CT.
tumour Recurrence
Two out of 11 (18%) patients developed soft tissue tumour recurrence 6 and 9 months postoperatively. Both patients reported vague discomfort and underwent MRI. The tumours were poorly visible on follow-up radiographs but were clearly seen on MRI ( Figure  6 ). Both of these patients had a positive initial tumour response radiologically (in terms of osteosclerosis) and histologically (disappearance of giant cells). They both underwent lesion curettage, as did the remaining nine patients.
Histopathological Response
The pretreatment biopsied samples and post-treatment resected specimens were available for all patients for histopathological comparison. All patients assessed by histology had an excellent tumour response with marked reduction or complete disappearance of multinucleated osteoclast-like giant cells together with evidence of de novo bone matrix or new bone formation. A typical example is shown in Figure 7 .
DiSCUSSiON
Because RANKL is a key mediator of osteoclast activation, the RANK-RANKL interaction in GCTB is thought to participate in the growth of the tumour cells, possibly as a result of the production of growth factors by osteoclast-like giant cells through a paracrine loop. 8 The inactivation of osteoclasts by denosumab, a human monoclonal antibody that specifically inhibits RANKL, disturbs the bone destruction in patients with osteoporosis 9 and in malignant bone tumours, such as metastatic bone tumours 10 and multiple myelomas.
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Considering its mechanism of action, clinical efficacy of denosumab for GCTB had been expected.
In this single-centre retrospective review of denosumab treatment for GCTB, radiological and histopathological assessments yielded initial promising results with high rates of positive tumour response without major adverse drug reactions. Only two cases of tumour recurrence were detected, in which the underlying cause or mechanism of drug resistance was not determined. Our comparative observational analysis demonstrates that the marked osteosclerosis shown by radiographs and CT images reflects the devitalisation of giant cells and reactive bone formation. The radiographs have excellent sensitivity in assessing tumour response to denosumab treatment, which can explain the low number of CT examinations. Conversely, the findings obtained by contrast-enhanced MRI in pre-and post-treatment phases were similar, presenting similar enhancement patterns, extraosseous soft tissue components and tumour sizes. Contrastenhanced MRI, owing to its poor ability to delineate bony structures, is typically less useful than radiographs or CT in evaluating the osteosclerotic response of denosumab treatment for GCTB. A previous single case report on such a comparative approach also arrived at a similar conclusion.
2 In the present study, both cases of tumour recurrence were detected by MRI owing to the increased extraosseous soft tissue component, suggesting a pivotal role for MRI in tumour assessment after denosumab treatment and operation. Histological assessment of the lesion, despite the potential difficulty in excluding giant-cell rich osteosarcoma, remains the gold standard for assessing tumour response and for confirmatory diagnosis of the lesion before commencement of treatment.
To date, there have been few studies on concomitant evaluation of radiological and histopathological response to denosumab, and none of these studies were in Hong Kong. This concomitant assessment clarifies the strengths and weaknesses of each imaging modality in assessing tumour response. Two cases of tumour recurrence occurred despite initial good tumour response, emphasising the importance of continued tumour surveillance.
limitation
This study has several limitations. First, denosumab has only recently come into clinical use for treatment of GCTB. As such, the study population is limited. Second, this was a single-arm study with no control group for comparison; it is difficult to determine whether the apparent improvement in tumour characteristics was due to natural disease progression or due to genuine improvement with denosumab. This would be solved if there were a control group receiving placebo treatment but this would be technically difficult due to the limited available study population. A double-blind randomised controlled trial with a larger patient cohort should be considered for future study. Third, core biopsies used for assessment of treatment response may not always provide representative specimens. However, this study establishes the therapeutic potential of denosumab to inhibit progressive bone destruction in patients with GCTB and also provides key insights into its biology.
Future Direction
Questions remain concerning the use of denosumab drug for treating GCTB. Denosumab is useful in the neoadjuvant setting, but the optimal duration and dose of neoadjuvant and adjuvant treatment remains to be refined via robust clinical trials. Moreover, the longterm effects of denosumab therapy on patients with normal bone density are unknown. Although patients with osteoporosis have been treated for many years, this situation is different from patients with bony metastases and GCTB, who generally have normal bone densities. Just as with any other clinical treatment option, the importance of clinical vigilance must be emphasised.
CONClUSiON
Denosumab is an efficacious treatment for GCTB in terms of clinical, radiological, and histopathological response with no recognisable complications, and this is confirmed by the present study conducted in Hong Kong. Radiographs and CT were helpful for evaluating the efficacy of denosumab treatment, whereas MRI was more useful for postoperative tumour surveillance.
